Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis

Background and purpose Nabiximols (Sativex®) is a cannabinoid‐based compound used for the treatment of moderate to severe spasticity in multiple sclerosis (MS). The aim of the study was to investigate the effect of the administration of Nabiximols on blood transcriptome profile of patients with MS a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of neurology 2018-07, Vol.25 (7), p.934-e70
Hauptverfasser:	Sorosina, M., Clarelli, F., Ferrè, L., Osiceanu, A. M., Unal, N. T., Mascia, E., Martinelli, V., Comi, G., Benigni, F., Esposito, F., Martinelli Boneschi, F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Blood Cannabidiol - pharmacology Cannabidiol - therapeutic use Cannabinoids Down-Regulation Dronabinol - pharmacology Dronabinol - therapeutic use Drug Combinations Female Fyn protein Gene expression Genomes Humans Immune system Immunomodulation Inflammation Interferon Leukocytes (mononuclear) Leukocytes, Mononuclear - drug effects Leukocytes, Mononuclear - immunology Male Middle Aged Molecular chains Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis - immunology Nabiximols Network analysis p53 Protein Patients Peripheral blood mononuclear cells Sativex Spasticity transcriptomics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!